Yelak Biru

Diagnosed at the young age of 25 with stage III multiple myeloma, Yelak Biru is a patient turned myeloma research advocate. Working with a team of medical practitioners and educating himself through support group leadership, information resources, advocacy sites, social media, and the IMF, Yelak has successfully integrated myeloma to his life for over two decades.

Follow Yelak on Twitter

Dara, the new Bacon…I mean, Beacon of Myeloma

Yelak Biru |

One of the late-breaking abstracts presented by Dr. Saad Usamani compared Kyprodlis and dexamethason (Kd) with Kd and daratumumab. There were many trial results that were presented at ASH that showed Dara makes many drugs better. Combining Dara with KRd seems to result in an “unprecedented” level of response and MRD negative response for newly […]

Pandora’s Box of Myeloma Treatment

Yelak Biru |

Over the last two decades, the treatment landscape for multiple myeloma has changed significantly. In the 1990s there were no approved novel therapies for myeloma. Since 2003 there have been over 11 treatments approved for the treatment of myeloma (in the United States). With those approvals, the treatment algorithms have become very complex. After the […]

Four years ago….

Yelak Biru |

“During a two-week span in November, the Food and Drug Administration approved three new drugs to treat multiple myeloma, a rare form of blood cancer that kills an estimated 11,000 Americans a year. The approvals, along with others in recent years, are beginning to alter the prognosis of a disease that once amounted to a death […]